Results 191 to 200 of about 59,667 (304)

Polymer Nanofibrous Material for Enzyme Immobilization [PDF]

open access: yes
Novák Josef, Martinová Lenka
core   +1 more source

Balancing Stealth and Targetability: cCPP‐ and PEG‐Modified Liposomes for the Targeted Delivery of Anti‐HER2 Nanobodies

open access: yesAdvanced Science, EarlyView.
This study addresses the rapid renal clearance of anti‐HER2 nanobodies by developing specialized liposomal carriers. It details the formulation of dual modified liposomes, demonstrating how PEGylation preserves structural integrity and cell‐penetrating peptides enhance cellular interaction.
Giulia Pander   +14 more
wiley   +1 more source

Enzyme immobilization with plant-based polysaccharides through complex coacervation. [PDF]

open access: yesLebensm Wiss Technol
Khongkomolsakul W   +6 more
europepmc   +1 more source

A Plug‐and‐Play Platform for Customizing Multivalent Degraders and Degrader‐Drug Conjugates

open access: yesAdvanced Science, EarlyView.
Membrane proteins remain challenging targets for conventional TPD approaches. Here, the authors develop UPTAB, a modular platform leveraging ultrahigh‐affinity orthogonal Im/CL protein pairs for lysosomal degradation of membrane proteins. Mono‐targeted (Type‐I), dual‐targeted (Type‐II), and tri‐targeted (Type‐III) UPTABs enable simultaneous degradation
Mengqing Zhao   +7 more
wiley   +1 more source

Aptamer‐Targeted PrPC Drives Colorectal Cancer Metastasis via a LYN‐STAT3 Complex and Enables Liquid Biopsy Detection

open access: yesAdvanced Science, EarlyView.
The aptamer WHY‐3E identifies PrPC as a CRC driver. Stabilized by USP18, endocytosed PrPC forms a LYN/STAT3 complex, upregulating MSN transcription to promote metastasis. Crucially, WHY‐3E sensitively detects PrPC‐positive circulating exosomes, establishing a robust theoretical foundation for non‐invasive clinical diagnostics.
Chunlin Wang   +23 more
wiley   +1 more source

Home - About - Disclaimer - Privacy